COVID-19 left behind a long list of victims: families who lost loved ones, businesses that collapsed, healthcare workers who worked beyond exhaustion and a country that struggled to keep its healthcare system standing.
But the pandemic also produced another phenomenon the rapid expansion of a transnational ecosystem of journalists, researchers, activists and civil-liberties organisations working on India’s public-health and pharmaceutical sectors.
At the centre of one such network is a controversial and fascinating figure: Dinesh Thakur, the former Ranbaxy executive who became a celebrated US whistleblower after exposing serious regulatory and data-integrity violations at the Indian pharmaceutical company.
Thakur received $48.6 million from the US government as a whistleblower award after Ranbaxy agreed in 2013 to pay $500 million to resolve criminal and civil allegations involving fraudulent drug data and manufacturing violations.
Super Boss, Boss and Puppets (Thread)
2020-21
COVID was a painful memory for many, but it proved jackpot for few people. While India was fighting its worst challenge ever, a man sitting in the USA was quietly building his army in IndiaAn army of activists.
1/25 pic.twitter.com/05BqQWirGA
— STAR Boy TARUN (@Starboy2079) August 7, 2026
That episode established Thakur as a powerful voice on pharmaceutical regulation.
But the more intriguing story begins later. It concerns what happened when a portion of that influence was converted into philanthropy and when an American foundation began funding journalists, researchers, lawyers and civil-society organisations working in India.
The question is: What happens when the same ecosystem repeatedly funds reporting on one of the most strategically important sectors of the Indian economy pharmaceuticals while the reporting frequently focuses on Indian drug manufacturers and regulators?
And perhaps the biggest question of all, Where does legitimate public-health advocacy end and agenda-setting begin?
The Ranbaxy story is well documented.
Dinesh Thakur joined Ranbaxy in the early 2000s and later raised concerns about alleged manipulation of data and regulatory violations. The US Department of Justice eventually reached a landmark settlement with Ranbaxy in 2013.
The company agreed to pay $500 million. Thakur was awarded $48.6 million for his role as a whistleblower. There is no dispute that Ranbaxy faced serious allegations and that the settlement was enormous.
But the aftermath created something unusual. A former pharmaceutical insider suddenly possessed not merely credibility, but substantial financial resources. And Thakur subsequently moved into the world of public-health advocacy, pharmaceutical regulation and civil society.
The Thakur Family Foundation became one of the vehicles through which this influence was exercised. The Foundation describes itself as an independent funding organisation focused on public health and civil liberties in India.
Its own grant records show that it has supported investigative journalism, public-health reporting, research and civil-society work. This is where the story moves beyond one whistleblower and becomes a story about an ecosystem.
The Foundation’s publicly available grant records show funding to a substantial number of individuals and organisations working on Indian public-health and civil-liberties issues. Among them are media organisations and journalists.
Scroll Media Inc. received a public-health reporting grant in 2020. The Foundation’s own website lists stories produced under the grant, including reports on COVID-19 testing, hospitals, India’s drug regulator, vaccine trials and contact tracing.
In fact, Scroll’s receipt of the grant was disclosed. But it establishes something important, Foreign philanthropic money was funding journalism about India’s healthcare system during one of the most consequential periods in modern Indian pharmaceutical history.
And the funding was not limited to institutions. Individual journalists were also supported.
The Wire, for example, explicitly disclosed that a story by science journalist Priyanka Pulla was funded through a public-health journalism grant from the Thakur Family Foundation. Another Wire investigation on India’s drug-testing system likewise carried a disclosure that its reporting was supported by a Thakur Family Foundation grant.
Again, the existence of funding is not evidence that a story was false. But funding creates a relationship. And relationships deserve scrutiny. Priyanka Pulla’s work provides one of the clearest examples of how this ecosystem operated. During COVID-19, she produced extensive reporting on India’s health system, drug regulation, COVID deaths, vaccines and pharmaceutical quality.
Some of this work was explicitly supported by Thakur Foundation grants. The Foundation itself acknowledges the funding. That matters because the central issue here is not whether Pulla’s individual stories were correct or incorrect.
The issue is whether readers were adequately equipped to understand the **financial architecture behind the journalism.
If a foundation has a particular interest in pharmaceutical regulation, and that foundation funds reporting on pharmaceutical regulation, the relationship should be examined just as closely as the relationship between a corporate advertiser and a news organisation.
Not because funding automatically corrupts journalism. But because transparency is the minimum requirement for trust.
The Wire and the Covaxin Controversy
The question became particularly explosive during the COVID-19 vaccine controversy. The Wire published a series of reports concerning Bharat Biotech and Covaxin.
In February 2022, Bharat Biotech filed a Rs 100-crore defamation suit against The Wire and others over 14 articles. A Telangana court subsequently ordered the removal of the 14 articles and restrained further publication of allegedly defamatory material pending proceedings. The Wire disputed the order and argued that it had not been given an opportunity to respond before the ex parte order.
A court ordering removal of articles in an interim proceeding is not the same thing as a final judicial finding that every allegation in those articles was false. But the episode nevertheless demonstrates the intensity of the pharmaceutical information war that unfolded during COVID-19.
On one side were Indian vaccine manufacturers attempting to establish credibility for domestically developed products. On the other were journalists, activists and researchers questioning regulatory decisions, clinical evidence and pharmaceutical standards. And operating within that environment was a growing network of philanthropic funding.
The Scroll Connection
The Foundation’s own grant database records a public-health reporting award to Scroll Media Inc. in June 2020. The listed projects included:
- COVID-19 testing capacity in eastern Uttar Pradesh
- COVID-19 transmission in Kashmir
- Conditions inside Delhi COVID hospitals
- Dexamethasone and COVID treatment
- India’s drug regulator
- Changes in Delhi’s COVID response
- Vaccination and nutrition among children
- Criticism surrounding India’s vaccine-trial timeline
- Contact tracing as COVID cases increased
These are all legitimate subjects for journalism. But the concentration is revealing. During a national crisis, the Foundation was financing journalism examining India’s healthcare response, pharmaceutical regulation and vaccine policy.
The question therefore becomes, Was this simply philanthropic support for journalism or was it also helping shape which aspects of India’s pharmaceutical system received sustained scrutiny?
The evidence establishes the funding relationship.The motive behind individual grants, however, requires further investigation rather than assumption.
ALT News Connection
The network also extended into fact-checking and evidence-based medicine. The Foundation’s grant records state that it awarded a grant to neuroscientist and author Dr Sumaiya Shaikh to support fact-checking claims related to evidence-based medicine. The listed work included COVID-19 misinformation and claims involving traditional or alternative medicine.
During the pandemic, India’s AYUSH Ministry had issued advisories involving traditional systems of medicine. Then comes Saurav Das. Das became known for filing RTIs relating to India’s COVID-19 vaccine approval process.
In 2021, he sought information concerning the regulatory basis on which vaccines developed by Bharat Biotech and Serum Institute of India received approval. The government refused to provide portions of the requested information, citing grounds including commercial confidence, trade secrets, intellectual property and fiduciary relationships.
Das continued to pursue questions concerning vaccine approvals and the government’s COVID-19 decision-making process.
And in October 2021, according to publicly available Foundation records, Das became a recipient of Thakur Foundation funding for public-health reporting. Later grant records also show additional funding.
The Foundation’s grant records go considerably beyond the names that attract the most attention. Its publicly listed recipients include journalists, researchers, lawyers, civil-liberties organisations and media organisations.
PFIZER question
The collapse of Ranbaxy’s position in the global generic market undoubtedly had enormous consequences for pharmaceutical competition. But it would be a leap to conclude from this alone that Thakur was acting for Pfizer.
A company benefiting from the consequences of another company’s regulatory downfall does not establish that the whistleblower worked for that beneficiary. That distinction matters. The stronger question is:
“Has Thakur’s post-Ranbaxy career created an advocacy and funding ecosystem whose work frequently intersects with the interests of the global pharmaceutical industry, and has that ecosystem been sufficiently transparent about potential conflicts?”.
India is one of the world’s most important suppliers of generic medicines. Its pharmaceutical industry is strategically important not merely for Indian consumers but for patients across the developing world.
That industry must absolutely be investigated when companies violate manufacturing standards, manipulate data or produce unsafe medicines. Ranbaxy is itself a reminder of why regulation matters.
If every problem in India’s pharmaceutical sector becomes evidence that the entire Indian generic industry is inherently corrupt, the result can be damaging to legitimate manufacturers as well. The answer cannot be blind nationalism. Nor can it be blind faith in foreign-funded activism. The answer has to be radical transparency.
These are questions that every recipient of foreign philanthropic funding should be prepared to answer.
The US government awards him $48.6 million. He later establishes a foundation focused on public health and civil liberties. That foundation funds Indian journalists, researchers, activists and media organisations.
Some of those recipients produce substantial reporting on India’s pharmaceutical industry, drug regulators, COVID policy and vaccines. Some recipients continue to receive grants years later. The Foundation itself publishes many of these relationships. But it is certainly a funding network worth investigating. Because in the pharmaceutical industry, information is not merely information.
It can influence regulation. It can influence public confidence. It can influence investors. It can influence vaccine acceptance. It can influence the reputation of an entire national industry. And ultimately, it can influence who wins and who loses in a multibillion-dollar global market.
